# Safety and Efficacy Study Using Bevacizumab, Capecitabine and Oxaliplatin for Colorectal Cancer

> **NCT00177307** · PHASE2 · COMPLETED · sponsor: **University of Pittsburgh** · enrollment: 40 (actual)

## Conditions studied

- Cancer

## Interventions

- **DRUG:** Bevacizumab
- **DRUG:** Capecitabine
- **DRUG:** Oxaliplatin

## Key facts

- **NCT ID:** NCT00177307
- **Lead sponsor:** University of Pittsburgh
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-01
- **Primary completion:** 2012-02
- **Final completion:** 2012-02
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2016-07-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00177307

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00177307, "Safety and Efficacy Study Using Bevacizumab, Capecitabine and Oxaliplatin for Colorectal Cancer". Retrieved via AI Analytics 2026-08-02 from https://api.ai-analytics.org/clinical/NCT00177307. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*